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PHOTOCHEMOTHERAPY OF VASCULAR CELLS WITH 8-METHOXYPSORALEN AND
VISIBLE LIGHT: A NOVEL APPROACH TO THE PREVENTION OF POST-ANGIOPLASTY
RESTENOSIS
David M. Lee, Francis P. Gasparro, and Bauer E. Sumpio. Section of Vascular Surgery, Department
of Surgery, Yale University, School of Medicine, New Haven, CT.
The purpose of the present study was to evaluate the effects of photochemotherapy with 8methoxypsoralen (8-MOP) and visible light (447 nm) on vascular cells in vitro. It was hypothesized that this
treatment regimen could selectively inhibit smooth muscle cell proliferation and might thus represent a novel
approach to the prevention of post-angioplasty restenosis.
Bovine aortic smooth muscle cells (SMC) and endothelial cells (EC) were cultured in cell wells,
incubated with 1, 20, or 50 pg/mL 8-MOP, and then exposed to 12.0 J/cm2 447 nm visible light. Control cells
were wrapped with aluminum foil so as to prevent 8-MOP photoactivation. Studies were then undertaken to
ascertain the effects of these treatment regimens on SMC and EC proliferation, migration, morphology, size,
and photoadduct formation.
Experiments on SMC proliferation revealed no significant effect at 1 pg/mL 8-MOP, while 20
pg/mL produced a transient, reversible inhibition, and 50 pg/mL resulted in cell death. Experiments on EC
proliferation also revealed no significant effect at 1 pg/mL 8-MOP; however, a transient, reversible
inhibition was seen at both 20 and 50 pg/mL 8-MOP. Further experimentation revealed that photoactivated
8-MOP does not inhibit cell migration. Morphology studies demonstrated both size and phenotype changes
induced by higher dosages (20 and 50 pg/mL) of 8-MOP. Cell size measurements corroborated the cell
enlargement observed in the morphology studies. Followed over time, EC revealed a return to baseline sizes
while SMC remained enlarged. Finally, studies on photoadduct formation revealed the formation of
comparable numbers and types of photoadducts between SMC and EC.
These experiments demonstrate that while 8-MOP photoactivated with 447 nm visible light can
reversibly inhibit the proliferation of both SMC and EC in a dose-dependent fashion, SMC are more
sensitive to the treatments than EC. The rapidly reversible inhibition observed in EC proliferation bears
clinical significance, as previous studies have demonstrated that an intact endothelium contributes to the

inhibition of SMC proliferation. As SMC proliferation constitutes a major mechanism by which restenosis
after angioplasty occurs, the results of this study suggest that photochemotherapy with 8-MOP and visible
light may represent a novel approach to the prevention of post-angioplasty restenosis.
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3

1. Percutaneous Transluminal Coronary
Angioplasty (PTCA)

The Normal Coronary Artery
Coronary artery disease remains the number one cause of morbidity and mortality in the
Western world. It results from the development of atherosclerotic lesions in the coronary
arteries, or vessels which supply the heart. The anatomy of the normal coronary artery is
no different from that of other medium-sized arteries in the human body; namely, the
vessel wall possesses three layers—an intima, media, and adventitia.

fTintima
viL
media
adventitia
'

Figure 1-1. Schematic representation of the three layers of the coronary artery. Figure modified from Libby,
1992.
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The intima is the layer closest to the lumen of the vessel and is primarily comprised of a
monolayer of endothelial cells (EC) lining an underlying coat of connective tissue. It is
separated from the media by a fenestrated membrane through which the smooth muscle
cells (SMC) of the media can migrate, called the internal elastic membrane. The media, or
muscular layer, of the artery forms the major structural support for the vessel and consists
of several layers of SMC separated by compact, fenestrated layers of elastic tissue. A
condensation of this elastic tissue at the perimeter of the media forms the external elastic
membrane, which separates the media from the outermost layer of the artery, the
adventitia. A poorly defined layer of connective tissue, the adventitia contains fibroblasts,
elastic fibers, nerve fibers, and small nutrient vessels known as vasa vasora. These thinwalled vessels serve as the blood supply to the adventitial layer and to the outer portion of
the media.

The Diseased Coronary Artery: Atherosclerosis
The hypothesis that an injury to the endothelium is the precipitating event in the
development of atherosclerosis was first formally proposed in 1973 by Ross and Glomset
(Ross and Glomset, 1973) and is still widely held today.

Commonly cited potential causes of injury include diabetes, hypertension, tobacco,
radiation, and hyperlipidemia. Over the past two decades, our understanding of the
pathogenesis of atherosclerosis has substantially increased and been refined by
accumulating observations on the various cell types and molecules involved in
atherogenesis.
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Figure 1-2. Schematic representation of the response-to-injury hypothesis of atherosclerosis. Several
different sources of injury to the endothelium can lead to the formation of a fatty streak, which can
ultimately progress to a fibrous plaque. Each of the stages of lesion formation is potentially reversible.
Thus, lesion regression can occur if the injurious agents are removed or when protective factors intervene to
reverse the inflammatory and fibroproliferative processes. Figure taken from Ross, 1993.

The earliest recognizable lesion of atherosclerosis is the “fatty streak,” which consists of
an aggregation of lipid-laden macrophages, or foam cells, in the intima.
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Figure 1-3. Schematic representation of a fatty streak. Figure modified from Libby, 1992.

Presumably, this lesion progresses as SMC migrate from the media into the intima and
elaborate a connective tissue matrix. This results in the projection of the lesion, now
termed a “fibrous plaque,” into the arterial lumen. Eventually, extracellular cholesterol,
calcium deposits, and necrotic cellular debris accumulate with the foam cells at the core
of the lesion. Finally, the plaque is covered over by a dense fibrous cap made of
connective tissue embedded with SMC (Ross, 1993; Lovqvist et al., 1993).

It is important to note that the majority of atherosclerotic lesions are eccentric rather than
concentric; that is, the majority of lesions involve only a portion of the arterial
circumference rather than the entire circumference (Waller, 1985).
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Figure 1-4. Atherosclerotic lesions in coronary arteries. A: an eccentric lesion (bottom) with disease-free
segment (top). B: markedly calcified concentric plaque. Figure taken from Edwards, 1995.

An increase in size in one of these fibrous plaques causes arterial stenosis, or a narrowing
of the arterial luminal cross-sectional area. This, in turn, results in an increased resistance
to blood flow. When present to a sufficient degree in coronary arteries, these stenotic
lesions may cause symptoms of stable angina. Fissures or ruptures in the fibrous cap, on
the other hand, may result in hemorrhage into the plaque, thrombosis, and acute arterial
occlusion. This latter sequence is responsible for the majority of sudden deaths caused by
myocardial infarcts (Davies and Thomas, 1984).

Advances in PTCA
Non-pharmacologic therapies for symptomatic coronary artery disease include coronary
artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty
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(PTCA). Whereas surgical bypass is the standard of care in cases of left main coronary
artery disease, triple vessel disease with compromised ventricular function, and anginal
symptoms resistant to medical therapy, PTCA has been established as a significant option
in the treatment of patients with coronary artery disease. Up to 50% of all patients
requiring revascularization choose this considerably less invasive procedure as an
alternative to bypass surgery (Ip et al., 1990).

Balloon angioplasty, the most common form of PTCA, involves the passage of a balloon
along a guide wire to a site of arterial stenosis. Subsequent dilation of the balloon
typically produces a stretching of plaque-free wall and fracturing or “cracking” of plaque
and hence a widened lumen diameter.

First introduced in September 1977 by Andreas Gruentzig (Gruentzig et al., 1979), PTCA
was initially received with skepticism. Today, it has become the treatment of choice for
many patients with coronary artery disease who require revascularization (Lange et al.,
1993).
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Figure 1-5. Mechanisms by which balloon angioplasty can induce revascularization. Ao = aorta; LAD = left
anterior descending; LC = left circumflex; LM = left main coronary artery. Figure taken from Waller, 1985.

Formerly limited to cases involving simple single-vessel disease, PTCA has now been
applied in cases involving complex stenoses, occluded arteries, multivessel disease,
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saphenous vein grafts, and acute myocardial infarction (Lange et al, 1993). Despite its
application in increasingly complex cases, improvements in technique and advances in
catheter technology have continued to improve the success rate of this procedure. With a
primary success rate of nearly 95% (Hermans et al., 1991), over 350,000 coronary
angioplasty procedures are being performed each year in the United States (Faxon and
Currier, 1995). The long-term efficacy of this minimally invasive treatment modality,
however, continues to be severely limited by the problem of post-angioplasty restenosis.
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2.

Restenosis: The Achilles’ Heel of PTCA

Restenosis: The Problem
Restenosis is the re-narrowing of a segment of artery formerly subjected to a
percutaneous intervention such as balloon angioplasty.

Figure 2-1. Atherectomy specimen from femoral artery of a patient who developed restenosis after balloon
angioplasty. A: S = zone of SMC proliferation; L = acellular lipid core of the plaque; F = deeper fibrous
region. B: arrow pointing to region of intense SMC proliferation. Figure taken from Forrester et al., 1991.

Traditionally, restenosis rates have been quoted to range anywhere from 5% to 50%. A
more contemporary view of restenosis, however, holds that it actually occurs in all
patients who undergo PTCA (Ip et al., 1991; Lovqvist et al., 1993) and that its clinical
significance is merely a matter of extent. A recent angiographic follow-up study which
revealed a near-gaussian distribution of luminal narrowing following PTCA (Rensing,
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1992) supports this notion that restenosis is a continuous process rather than “all or
nothing” phenomenon.

Figure 2-2. Histogram of per cent diameter stenosis seen at follow-up angiography in 1,445 lesions. The
curve superimposed on the histogram represents the theoretic gaussian distribution curve. Figure modified
from Rensing et al., 1992.

Restenosis: The Economic Impact
A major cause of morbidity, restenosis manifests most frequently as recurrent
symptomatic angina requiring additional revascularization procedures. A treatment
capable of reducing the risk of restenosis by 25% would average a calculated savings of
$1400 per patient in hospital, procedural, and professional fees, while a risk reduction of
33% would save $2000 per patient (Califf, 1995). Accordingly, the magnitude of the
problem of restenosis, in terms of health care costs, exceeds one billion dollars annually
in the United States alone (Faxon and Currier, 1995).

13

Restenosis: Temporal Considerations
Restenosis can be classified as early or late depending on the histopathology of the
restenosed arterial wall. Pathologic examinations of restenosis sites from patients who
died after successful PTCA have revealed two types of lesion: those with only fibrous
atheromatous plaques resembling the primary plaque and those with substantial intimal
thickening secondary to SMC proliferation and matrix elaboration (Waller et al., 1991).
The former is associated with early restenosis and the latter with late restenosis (Lovqvist
et ah, 1993; Lange et ah, 1993).

Early Restenosis: Thrombosis, Recoil, and Vasoconstriction
Early restenosis occurs within days of PTCA. One mechanism by which it is thought to
occur involves thrombus formation. The mechanical disruption of the intima caused by
balloon angioplasty results in endothelial denudation of the plaque. This, in turn,
promotes platelet aggregation and may precipitate the acute formation of a thrombus
(Lovqvist et ah, 1993).

An alternative mechanism in the pathogenesis of early restenosis involves the relaxation
and vasoconstriction of stretched plaque-free portions of artery. A quantitative
angiographic assessment of coronary arteries before, during, and immediately after
angioplasty revealed that nearly 50% of the maximal luminal cross-sectional area
achieved during PTCA is lost shortly after balloon deflation, and this presumably due to
elastic recoil (Rensing et ah, 1990). Additionally, the arterial vasoconstriction frequently
observed at the site of coronary angioplasty (Bertrand et ah, 1989) may be attributable
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both to a decrease in vasodilators produced by disrupted endothelial cells and to an
increase in vasoconstrictors released by platelets (Lange et al., 1993).

Late Restenosis: Vascular Wound Healing
A complete understanding of the biologic mechanisms involved in the pathogenesis of
late restenosis has yet to be established; however, several of the mechanisms which are
involved in the process have been elucidated. Balloon angioplasty is known to inflict
substantial injury on the intima and media of the vessel wall, and it is becoming
increasingly accepted that the process of restenosis can be understood as a “wound
healing” response to such injury (Serruys et al., 1988; Forrester et al., 1991; Ip et al.,
1991; Clinton and Libby, 1992; Faxon and Currier, 1995). The ultimate result of this
wound healing response is the formation of a neointima consisting of an increased mass
of smooth muscle cells (SMC) scattered through a loose extracellular matrix. This
neointima formation is the mechanism by which late restenosis occurs.

Phase I of Vascular Wound Healing: Inflammation
It has been suggested that the process of late restenosis occurs over a series of three
phases: inflammation, granulation, and matrix formation (Forrester et al., 1991). The first
phase, known as the inflammation phase, occurs almost immediately after the injury and
continues for several days. It begins with platelet aggregation at the site of the wound
surface and thrombus formation (Wilentz et al., 1991). As the blood and soluble serum
fibronectin coagulate to form an extracellular matrix, the activated platelets release
platelet-derived growth factor (PDGF), a major stimulus of SMC migration and
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INFLAMMATION
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Figure 2-3. Hypothetical schema for late restenosis. PDGF = platelet-derived growth factor; TGF =
transforming growth factor; Polys = polymorphonuclear cells; SMC = smooth muscle cells; EC =
endothelial cells. Figure taken from Forrester et al., 1991.

proliferation, and other mitogenic factors, including epidermal growth factor and beta
transforming growth factor (Ip et al., 1991). Monocytes soon collect in the area of injury
and release additional growth factors (Forrester et al., 1991). Meanwhile aggregated
mononuclear lymphocytes contribute cytokines such as tumor necrosis factor,
interleukins, and beta transforming growth factor (Ip et al., 1991). The release of these
various cytokines and growth factors results in a local milieu capable of stimulating SMC
migration and proliferation and extracellular matrix production. Hence, the stage is set for
the next phase of restenosis.

Phase II of Vascular Wound Healing: Granulation
The second phase of restenosis, called the granulation phase (Forrester et al., 1991), lasts
approximately one week and primarily involves the migration and proliferation of SMC.
Initial SMC proliferation is reported to begin as early as 24 to 48 hours following
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vascular injury. Two to three days later, SMC begin to migrate to the intima, where they
may continue to proliferate (Lange et al., 1993).

The stimulus for SMC migration and proliferation is multifactorial and, in addition to the
presence of growth factors described above, involves endothelial disruption and direct
damage to the EC and SMC. The intimal disruption associated with PTCA may promote
SMC proliferation by removing the growth-inhibitory influences exerted by an intact
endothelium (Ip et al., 1991). Confluent EC have been observed to secrete heparin-like
glycosaminoglycans (Castellot et al., 1981), while exogenous heparin has been shown to
inhibit SMC proliferation in injured arteries (Clowes and Karnowsky, 1977). Put
together, these facts suggest that a functionally intact endothelium can inhibit SMC
growth (Ip et al., 1990). Hence, endothelial disruption, in addition to the presence of
mitogens and growth factors, may promote SMC proliferation.

Damaged EC and SMC may also contribute to the mitogenic activity of healthy SMC. EC
have the ability to secrete at least two major mitogens, one of which closely resembles
PDGF. Meanwhile, SMC also possess the ability to produce a PDGF-like protein. It has
been reported that dying EC can produce greater than six times the amount of growth
factors produced by healthy EC. Likewise, SMC isolated from injured segments of artery
have been found to produce PDGF-like substances on the order of ten times that released
by SMC from uninjured segments (Ip et al., 1990).

It should be noted that the SMC proliferating at the site of arterial injury are of the
synthetic, rather than contractile, phenotype. Contractile-phenotype SMC predominate in
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healthy adult vascular media, whereas synthetic-phenotype SMC exist in young
developing arteries. Synthetic-phenotype SMC are closely related to fibroblasts and
possess abundant synthetic organelles including free ribosomes, rough endoplasmic
reticula, and Golgi apparati (Forrester et ah, 1991). They are “synthetic” in the sense that
they synthesize and secrete large quantities of extracellular matrix collagen, elastin, and
proteoglycans. These synthetic SMC are the primary cell type involved in the final phase
of the wound-healing response, the matrix formation phase.

Occurrence

SYNTHETIC PHENOTYPE

Structure

Function

embryo and
young growing
organism

euchromatic
nucleus

proliferation

atherosclerotic
lesions

prominent ER
and Golgi complex

synthesis and secretion
of extracellular matrix
components

heterochromatic
nucleus
abundant actin and
myosin filaments

contraction in
response to
chemical and
mechanical stimuli

normal
development

atherogenesis

CONTRACTILE PHENOTYPE

adult organism

Figure 2-4. Diagrams comparing contractile- and synthetic-phenotype SMC. ER = endoplasmic reticulum.
Figure taken from Thyberg et al., 1990.

Phase III of Vascular Wound Healing: Matrix Formation
The matrix formation phase of restenosis primarily involves extracellular matrix
deposition and remodeling. As the surface of the site of injury becomes covered with a
layer of cells, the SMC which have migrated to the wound area slow their proliferation
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and begin to deposit large amounts of proteoglycan, most notably chondroitin sulfate and
dermatan sulfate. Neighboring EC also contribute heparin sulfate proteoglycan to the
extracellular matrix deposit. Over a course of months, these proteoglycans become
replaced by large bundles of type I collagen and elastin (Forrester et al., 1991). This
replacement of proteoglycan by collagen and elastin constitutes remodeling and signifies
the completion of the final phase of restenosis.
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3. Pharmacologic Approaches to the Prevention
of Restenosis
The amount of time it takes to advance through the three phases of restenosis described in
the previous chapter is somewhat variable, but the entire process of neointima formation
is reported to be largely complete by 90 to 120 days (Forrester et al., 1991).

(Days)

INFLAMMATION

GRANULATION

MATRIX FORMATION

Figure 3-1. Time course for the three phases of wound healing. Figure modified from Forrester et al., 1991.

The fact that this process occurs over a multiplicity of steps suggests that the problem of
restenosis can potentially be addressed at a number of levels. Accordingly, a variety of
drugs aimed at reducing platelet adhesion, thrombosis, fibrin formation, growth factor
expression, and SMC proliferation have been suggested (Ip et al., 1990; Hermans et al.,
1991).
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Multiple classes of drug have been studied in experiments aimed at reducing or
preventing post-angioplasty restenosis. These include antiplatelet agents, antithrombotic
agents, lipid-lowering agents, antispamodic agents, antineoplastic agents, and
antiproliferative agents. It should be noted that while many approaches have successfully
inhibited restenosis in rat or rabbit models, none have proven effective in pig or primate
models, and none have been successful at preventing restenosis in human clinical trials
(Wilcox et al., 1993).

Pharmacologic Approaches to Post-angioplasty Restenosis

aspirin

dipyridamole

ticlopidine

prostacyclin

thromboxane A2 inhibitors

monoclonal antibodies to GP llb/llla

heparin

low molecular weight heparin

warfarin

hirudin

cholesterol synthesis inhibitors

fish oils

nifedipine

diltiazem

vincristine

actinomycin D

methotrexate colchicine

glucocorticoids

cilazapril

angiopeptin

trapidil

Table 3-1. Summary of some of the different agents used in experiments designed to reduce or prevent
restenosis after angioplasty.
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Antiplatelet Agents
The antiplatelet agents studied have included aspirin, dipyridamole, ticlopidine,
prostacyclin, thromboxane A2 inhibitors, and monoclonal antibodies to the platelet
receptor GP Ilb/IIIa. The theoretical basis for their use in strategies designed to prevent
post-angioplasty restenosis is founded on the premise that inhibition of platelet deposition
may reduce SMC exposure to PDGF and other growth factors which can stimulate
neointima formation. One study examining the role of platelets in post-angioplasty
restenosis revealed that thrombocytopenic rabbits experienced a marked reduction in
intimal thickening following balloon-induced arterial injury (Friedman et al., 1977).

Aspirin, dipyridamole, and ticlopidine. Aspirin inhibits platelet aggregation by
irreversibly acetylating the enzyme cyclooxygenase, thereby suppressing the synthesis of
proaggregatory thromboxane A2. Dypyridamole acts by increasing intracellular levels of
cyclic AMP via the inhibition of cyclic nucleotide phosphodiesterase, which in turn may
potentiate prostacyclin’s ability to antagonize platelet adhesion to thrombogenic surfaces.
While the combination of aspirin and dipyridamole has been shown to decrease the
incidence of acute complications both during and after PTCA, it has proven ineffective in
preventing restenosis (Schwartz et al., 1988; Chesebro et al., 1989). Ticlopidine, which
acts by altering the platelet membrane such that ADP-induced exposure of the fibrinogen
binding site on platelet glycoprotein Ilb/IIIa is prevented, is another platelet inhibitor.
Studies using this agent have also failed to demonstrate beneficial effects on restenosis
(White et al., 1987).
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Prostacyclin and ciprostene. Prostacyclin is a naturally occurring arachidonic acid

metabolite which possesses both platelet inhibitory and vasodilatory properties.
Administration of prostacyclin shortly before PTCA and continued for 48 hours after
failed to reduce the incidence of restenosis (Knudtson et al., 1990). Likewise, short-term
administration of ciprostene, a prostacyclin analogue, failed to affect the incidence of
angiographically-determined restenosis, although some clinical benefit was noted
(Raizner, 1988).

Thromboxane A2 inhibitors. In addition to its proaggregatory effects on platelets,

thromboxane A2 has been shown to have a mitogenic effect on vascular SMC (Hanasaki
et al., 1990). Thromboxane A2 inhibitors work by blocking the formation of thromboxane
and redirecting the metabolism of prostaglandin endoperoxides toward prostacyclin
synthesis. A small, promising study suggested that thromboxane A2 synthetase inhibitors
might prove beneficial in preventing restenosis (Yabe et al., 1989). However, a
subsequent randomized, double-blind, placebo-controlled trial involving blockade of the
thromboxane A2-receptor revealed no reduction in incidence of restenosis (Serruys et al.,
1991).

Antibodies to GP llb/llla. Glycoprotein Ilb/IIIa is a platelet membrane receptor which

plays an important role in the adhesion of platelets to the vessel wall (Ip et al., 1990). It is
also involved in the binding of fibrinogen to platelets (Lovqvist et al., 1993). While the
administration of monoclonal antibodies to GP Ilb/IIIa has been found to prevent acute
thrombosis in the canine model (Bates et al., 1988), its effectiveness in preventing post-
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angioplasty restenosis in humans has not been demonstrated and is currently being
evaluated in ongoing clinical trials (Faxon and Currier, 1995).

Antithrombotic Agents
The antithrombotic agents studied have included heparin, low molecular weight heparin,
warfarin, and hirudin. The theoretical basis for their use in strategies designed to prevent
post-angioplasty restenosis involves the role that thrombus formation plays in both early
and late restenosis. As described in the previous chapter, acute thrombosis represents a
mechanism by which early restenosis may occur. Moreover, during thrombosis, thrombin
may become incorporated into both the arterial extracellular matrix and the thrombus
itself and can be gradually released during fibrinolysis. As thrombin has been
demonstrated to have mitogenic activity for SMC (Ip et al., 1991), it may thus play an
important role in the long-term stimulation of SMC proliferation.

Heparin. As mentioned previously, heparin has been found to inhibit SMC proliferation
in vivo (Clowes and Karnowsky, 1977). While standardly administered to patients during

and in the hours following PTCA to prevent acute coronary thrombosis (Lange et al.,
1993), heparin given for 18 to 24 hours has failed to demonstrate a reduction in incidence
of restenosis (Ellis et al., 1989).

Low molecular weight heparin. Low molecular weight heparin was found to reduce

restenosis after angioplasty in the rabbit model (Pow et al., 1989). However, one-month
treatments with subcutaneous low molecular weight heparin in a double-blind
randomized trial have proven ineffective at preventing restenosis (Faxon et al., 1992).
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Warfarin. Warfarin is a vitamin K antagonist which inhibits coagulation and thrombin

formation. Several small clinical trials evaluating the effects of warfarin given after
angioplasty have failed to demonstrate a decrease in restenosis (Franklin, 1993).

Hirudin. Hirudin is a potent antithrombotic agent which has proven to be more effective

than heparin in preventing thrombosis in animal models (Lovqvist et al., 1993). Its
effectiveness in preventing post-angioplasty restenosis has yet to be demonstrated (Faxon
and Currier, 1995).

Lipid-lowering Agents
The lipid-lowering agents studied have included cholesterol synthesis inhibitors and fish
oils. The theoretical advantage of a reduction in lipids in the prevention of post¬
angioplasty restenosis is based on the paradigm of accelerated atherosclerosis as a model
for restenosis (Ip et al., 1990).

Lovastatin. Lovastatin, a cholesterol synthesis inhibitor with antiprloiferative properties

(Gellman et al., 1991), had previously shown promise in its ability to reduce restenosis in
a randomized clinical trial (Sahni et al., 1989). A recently-completed large double-blind
controlled trial, however, casts doubt on its effectiveness at preventing post-angioplasty
restenosis (Weintraub et al., 1992).

Fish oils. Fish oils, rich in omega-3 fatty acids, are known to decrease LDL cholesterol

while simultaneously increasing HDL cholesterol. It has been suggested that fish oils may
reduce SMC proliferation by inhibiting EC production of a PDGF-like protein (Fox and
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DiCorleto, 1988). Several randomized clinical trials designed to evaluate the effects of
fish oils on restenosis have been performed and offer conflicting results. While nearly
half of the clinical trials to date involving fish oils have demonstrated some beneficial
reduction in restenosis (Franklin et al., 1993), a recently-completed randomized
controlled clinical study involving large doses of omega-3 fatty acids with a minimum of
two weeks pretreatment revealed that fish oils were not effective at inhibiting restenosis
(Faxon and Currier, 1995).

Antispasmodic Agents
The antispasmodic agents studied have included the calcium channel blockers nifedipine
and diltiazem. The theoretical basis for their application in strategies designed to prevent
post-angioplasty restenosis involves the contribution of coronary vasoconstriction and
vasospasm to the process of early restenosis.

Nifedipine and diltiazem. Despite some promising results in animal models, clinical trials

in humans have shown that neither nifedipine nor diltiazem demonstrates a beneficial
effect on restenosis (Whitworth et ah, 1986; O’Keefe et ah, 1991).

Antineoplastic Agents
The antineoplastic agents studied have included vincristine, actinomycin D, and
methotrexate. The rationale for their use in strategies designed to prevent post-angioplasty
restenosis is based on the ostensible ability of these agents to selectively injure dividing
SMC while leaving non-proliferating cells undamaged (Lovqvist et ah, 1993).

26
Vincristine, actinomycin D, and methotrexate. While successful in preventing SMC

proliferation after endothelial injury in animals (Barath et al., 1989), the potential clinical
toxicity of these drugs prohibits their realistic application in the human model.

Antiproliferative Agents
The antiproliferative agents studied have included colchicine, glucocorticoids, cilazapril,
angiopeptin, and trapidil. The theoretical basis for their use in strategies designed to
prevent post-angioplasty restenosis is derived from the principal role that SMC
proliferation plays in the process of late restenosis.

Colchicine. Colchicine interferes with proper microtubule function by binding tubulin,

the subunit protein of microtubules. Consequently, it is a potent inhibitor of cell division.
While successful at preventing restenosis after balloon injury in various animal models
(Bilazarian et al., 1989), a recent randomized, placebo-controlled trial has shown that
colchicine is ineffective at preventing restenosis in humans (O’Keefe et al., 1992).

Corticosteroids. Steroids have well-characterized antiinflammatory and antiproliferative

properties. While hydrocortisone has demonstrated a synergistic inhibition of SMC
proliferation when combined with low molecular weight heparin (Gordon et al., 1987), a
multicenter controlled trial has revealed that corticosteroids yield no beneficial effect on
restenosis (Pepine et al., 1990).

Cilazapril. In addition to being a vasoconstrictor, angiotensin II is able to stimulate SMC

proliferation and matrix formation (Lange et al., 1993). Cilazapril, an angiotensin
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converting enzyme (ACE) inhibitor, has been shown to reduce restenosis in experimental
angioplasty (Bilazarian et al., 1991). However, two large multicenter trials evaluating the
long-term effects of cilazapril on restenosis have shown no difference between treated
and control patients (MERCATOR, 1992; Faxon et ah, 1992).

Somatostatin and angiopeptin. Somatostatin is a known potent inhibitor of growth

hormone secretion. Angiopeptin, a somatostatin analogue, has been shown to inhibit
myointimal proliferation in animal models following endothelial injury (Lundergan et ah,
1991). Multicenter trials in both Europe and the United States, however, have failed to
demonstrate any beneficial impact of angiopeptin on post-angioplasty restenosis (Faxon
and Currier, 1995).

Trapidil. Trapidil (triazolopyrimidine) possesses antiproliferative effects by virtue of its

ability to antagonize PDGF. Its success in preventing post-angioplasty restenosis in
atherosclerotic rabbits (Liu et ah, 1990) has prompted clinical trials. While two small
studies have shown trapidil to be effective at preventing restenosis (Okamoto et ah, 1992;
STARC, 1993), further investigation is warranted.

28

4. Photochemotherapy with 8-MOP and visible
light

Photochemotherapy
Photochemotherapy is a therapeutic modality that makes use of drugs which can be
pharmacologically activated by light. Upon irradiation, these drugs which possess low
intrinsic activity are transformed into highly reactive compounds. Photochemotherapy has
been used safely and effectively in the treatment of a variety of hyperproliferative skin
disorders for centuries. More recently, studies have been performed to assess the potential
efficacy of a variety of photochemotherapeutic agents in the control of SMC proliferation.

Chloroaluminum-sulfonated phthalocyanine. Chloroaluminum-sulfonated

phthalocyanine, a photosensitizer currently under evaluation for the treatment of
malignant lesions, has been shown to effectively reduce intimal hyperplasia in a rat model
(Ortu et al., 1992). While this treatment regimen demonstrates promise for potential
application in the prevention of post-angioplasty restenosis, its effectiveness in the human
model has yet to be investigated.

Hematoporphyrin compounds. Both in vivo and in vitro studies on the effects of

hematoporphyrin compounds on SMC proliferation have also suggested their potential
use in therapies designed to inhibit neointima formation (Litvack et ah, 1985; Dartsch et
ah, 1990). These compounds, however, are associated with a cutaneous phototoxicity for
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up to several weeks after administration. This has, in general, limited their clinical
application to experimental treatments involving certain malignant cancers (March et al.,
1993).

Photofrin. Photofrin is yet another photosensitizer which has been shown to successfully

reduce intimal hyperplasia in animals. Photoactivated with 630 nm light, Photofrin was
shown to decrease intimal thickening in a rabbit model by approximately 50% (Eton et
ah, 1992). The toxicity of Photofrin in humans, however, has yet to be resolved.
Moreover, a recent study demonstrating that photoactivated Photofrin can induce
microtubule depolymerization in human EC (Sporn and Foster, 1992) calls its suitability
for human application into question. As damaged EC contribute to the process of
restenosis by stimulating SMC proliferation (see “Phase II of Vascular Wound Healing:
Granulation,” Chapter 2), a more ideal treatment regimen might entail the use of a drug
which could selectively inhibit SMC proliferation without causing damage to EC.

8-Methoxypsoralen (8-MOP)
Photochemotherapy with 8-methoxypsoralen (8-MOP) dates as far back as the 15th
century B.C. Ancient manuscripts document the use of this compound, extracted from
psoralen-containing plants, in the treatment of vitiligo. Photoactivation during this time
was achieved via exposure to natural sunlight (Roelandts, 1991).

Today, photochemotherapy with 8-MOP has been approved by the Food and Drug
Administration (FDA) for the treatment of a variety of skin diseases. Treatment typically
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consists of oral or intravenous administration of 8-MOP followed by photoactivation with
high-intensity UVA bulbs in affected areas of skin.

Given its excretion rate of approximately 90% within the first 12 hours of administration
(Gupta and Anderson, 1987), 8-MOP exhibits minimal long-term phototoxicity. Its
established long-term safety and therapeutic efficacy have helped it to become the
foremost photosensitizer employed in all of photomedicine (Gasparro, 1990). While
photochemotherapy with 8-MOP is most commonly used in the treatments of psoriasis
and vitiligo, its clinical application has spanned more than 40 other diseases (Roelandts,
1991).
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Clinical applications of photochemotherapy with 8-MOP

acne vulgaris

ichthyosis

alopecia areata

impetigo herpetiformis

atopic dermatitis

lichen planus

basal-cell and squamous cell carcinoma

lymphomatoid papulosis

chronic actinic dermatitis

mycosis fungoides

chronic hyperkeratotic dermatitis

nodular prurigo

chronic urticaria

palmoplantar pustulosis

contact dermatitis

papuloerythroderma

Darier’s disease (keratosis follicularis)

parapsoriasis

disseminated superficial actinic porokeratosis

pityriasis alba

dyshidrotic eczema

pityriasis lichenoides

epidermodysplasia verruciformis

pityriasis rubra pilaris

erythema elevatum et diutinum

polymorphous light eruption

erythrodermia congenitalis progressiva symmetrica psoriasis
erythropoietic protoporphyria

purpura

follicular mucinosis

scleromyxedema

graft-versus-host-reaction

seborrheic dermatitis

granuloma annulare

solar urticaria

granuloma faciale

acantholytic dermatosis

Hailey-Hailey disease

urticaria pigmentosa

herpes

vitiligo

hydroa vacciniforme

warts

hyperkeratosis lenticularis persistans

Table 4-1. Summary of some of the indications for which photochemotherapy with 8-methoxypsoralen has
been applied. Table modified from Roelandts, 1991.
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8-MOP is a planar tricyclic furocoumarin. Its 5-member furan ring and 6-member pyrone
ring are connected linearly by a benzene ring.

Figure 4-1. Diagram of 8-methoxypsoralen. Figure taken from Gasparro, 1994.

When exposed to cells in darkness, 8-MOP molecules can easily diffuse into the nuclei
and intercalate between DNA base pairs. While inert in the dark, 8-MOP forms
photoadducts with DNA when exposed to light. These photoadducts represent the key to
8-MOP’s effectiveness in anti-proliferative photochemotherapies, as they presumably
cause an arrest in DNA synthesis (Roelandts, 1991) and hence cell replication.
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(a)

EST, A
□ G,C
E3 Sugars

Figure 4-2. Schematic demonstrating photoadduct formation by 8-MOP. a: Two 8-MOP molecules
intercalated between DNA base pairs. As 8-MOP forms photoadducts primarily with thymine, the upper
molecule is positioned to form a crosslink, while the lower molecule is positioned to form a 3, 4monoadduct. b: the upper molecule forms a 4’, 5’-monoadduct with the DNA. c: additional formation of a
3, 4-monoadduct converts the former 4’, 5’-monoadduct into a crosslink. Not all 8-MOP molecules form
photoadducts with the DNA, as seen in the lower molecule. Figures taken from Gasparro, 1994.

Three distinct types of photoadduct form between 8-MOP and DNA upon lightactivation. These include two types of monoadduct (a 4’, 5’-monoadduct and 3, 4monoadduct) and a crosslink.

4', 5' - MONOADDUCT

3,4- MONOADDUCT

0

CROSSLINK

Figure 4-3. Diagrams of the 4’, 5’-monoadduct; 3, 4-monoadduct; and crosslink. Figure taken from
Gasparro, 1994.

All three photoadducts are the product of 2+2 photocycloadditions to pyrimidine bases,
primarily thymine (Gasparro et al., 1990).

The absorption spectrum of 8-MOP has been measured over the range of 200-500 nm
with a peak absorbance found at the 200-300 nm wavelengths (Gasparro et al., 1993).
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WAVELENGTH, nm
Figure 4-4. Absorption spectrum for 8-MOP. Note the extinction coefficients corresponding to the
wavelengths with the filled squares are: 300 nm, 11800 cm'1 M1; 355 nm, 2016 cm 1 M *; 400 nm, 6.8 cm
M1; 419 nm, 0.60 cm'1 M1; and 447 nm, 0.22 cm'1 M'1. Figure taken from Gasparro, 1994.

While 8-MOP has traditionally been activated with long-wavelength ultraviolet radiation,
recent studies have shown that photoactivation with visible light results in a significant
reduction in crosslink formation. The percentage of crosslinks formed by 8-MOP
photoactivated at 419 nm is less than one fourth that formed when activated with
ultraviolet radiation (UVA, 320-400 nm), while the percentage of crosslinks formed by 8-

1
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MOP photoactivated at 447 nm is almost one fiftieth that formed when activated with
UVA.

Adduct Formation and Distribution in SMC

Wavelength (dose)
nm (J/cm )
UVA (2)
419 nm (7)
419 nm (12)
447 nm (12)

[8-MOP]

Total Adducts

(ig/mL

per mbp

1.0
1.0
1.0
20.0

88.0
9.0
13.5
22.4

4',5-MA

3,4-MA

41%
84%
78%
90%

12%
13%
12%
9%

XL

47%
3%
11%
1%

Table 4-1. Adduct formation and distribution in SMC. MA = monoadducts; XL = crosslinks. Table
modified from Sumpio et al., 1994.

It has been postulated that this reduction in crosslink formation may serve to reduce the
drug’s mutagenicity and hence enhance its therapeutic efficacy (Gasparro et al., 1993;
Sumpio et al., 1994).
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5.

Statement of Purpose

The purpose of the present study was to address the problem of post-angioplasty
restenosis by evaluating the effects of 8-MOP photoactivated with 447 nm visible light on
vascular cells (SMC and EC) in vitro.

The photosensitizer 8-MOP was chosen for its established long-term safety. As described
in the previous chapter, this FDA-approved drug is commonly used and well-tolerated in
therapies for a variety of dermatologic diseases. Its administration is associated with
minimal long-term phototoxicity secondary to a rapid clearance rate.

Photoactivation with visible light rather than ultraviolet light was favored for the
significant reduction in crosslink formation associated with visible-light photoactivation
(Gasparro et al., 1993; Sumpio et al., 1994). Additionally, visible light was chosen as it
offers both a deeper tissue penetration and superior compatibility with fiber-optic
applications than ultraviolet light.

The 447 nm wavelength used in the experiments was chosen primarily for the immediate
availability of the 447 nm laser. This laser is presently available on the market, as it is
being manufactured for application in other clinical scenarios.
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It is hypothesized that photochemotherapy with 8-MOP and visible light can result in the
selective inhibition of SMC proliferation and may thus represent a novel approach to the
prevention of post-angioplasty restenosis.
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6.

Experimental Methods3

Cell Culture
Bovine SMC and EC were obtained from calf thoracic aortas by means of a previously
described explant method (Sumpio and Banes, 1988). Thoracic aortas were removed
aseptically from calves and transferred on ice to a tissue culture facility. Under a laminar
flow hood, the peri-aortic fat was carefully trimmed and discarded. A longitudinal
incision was then made along the length of the aorta and the lumen exposed. After being
rinsed five to six times with Phosphate Buffered Saline (PBS), the EC were carefully
removed with a blade and placed in a culture dish containing growth media consisting of
Dulbecco’s Modified Eagle’s Medium F-12 (DMEM F-12) supplemented with antibiotics
(300 U/mL penicillin, 300 U/mL streptomycin), deoxycytidine/deoxythymidine, and 10%
(v/v) heat-inactivated fetal bovine serum. Following removal of the EC, the exposed
medial layer of aorta was rinsed thoroughly with PBS and 2 mm' biopsies obtained and
placed in a culture dish containing growth media consisting of Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with antibiotics (300 U/mL penicillin, 300
U/mL streptomycin), 0.2 M L-glutamine, and 10% (v/v) heat-inactivated fetal bovine
serum.

All procedures described in this methods chapter, barring those described in the Size and Photoadduct Formation section,
were performed by the author.
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Both cell types were then incubated at 37° C and 5% C02 until explants could be
detected. The presence of EC or SMC was confirmed by direct visualization via light
microscopy. SMC were identified by their typical hill-and-valley formation at confluency
and hence could be distinguished from fibroblasts, which exhibit a whorl-like appearance.

Both cell types were subcultured with 0.01% trypsin/ethylene diamino tetraacetic acid
(EDTA) and cultured on 75 cm2 tissue culture flasks, maintained in their respective
growth media as described above, and grown at 37° C and 5% C02. Cells used in the
experiments were obtained from subsequent passages subcultured with 0.01%
trypsin/EDTA. All experiments were performed using cells of passage seven or less.

Chemicals
A 1 mg/mL stock solution of 8-MOP (Sigma Chemical Co., St. Louis, MO) was prepared
in absolute ethanol. The different concentrations of 8-MOP used in the experiments were
obtained by appropriate dilution of this stock and subsequently verified by spectroscopy
or high-performance liquid chromatography (HPLC) analysis.

Experimental Protocol
Bovine aortic SMC or EC were detached and collected from the tissue culture flasks by
trypsinization with 0.01% trypsin/EDTA. They were then seeded in polystyrene 12-well
plates at a density of 5,000 to 10,000/cm2 and placed in an incubator at 37° C and 5%
C02. Following a 24-hour attachment period, the cells were rinsed once with Phosphate
Buffered Saline (PBS) and then incubated with 1, 20, or 50 pg/mL 8-MOP for 30 minutes

41

in the dark. The plates containing control cells were wrapped with aluminum foil prior to
incubation so as to prevent ambient light exposure.

All plates, including the control plates still wrapped in foil, were then exposed to 12.0
J/cm2 visible light (447 nm) in a photochemical reactor (Southern New England
Ultraviolet Co., Branford, CT) equipped with lamps spaced evenly over an arc at 22.5°
intervals. The light doses being administered were determined using a calibrated silicon
diode UV250BQ (EG&G, Montgomeryville, PA). Following irradiation, the 8-MOP
media was aspirated and replaced with fresh growth media, and the plates were returned
to the incubator. Growth media was aspirated and replaced with fresh media every 48
hours.

Cell Counts
Cell counts were performed on days 0, 1,3, 5, 7, 10, and 14 following the initiation of
each experiment. Growth media from each cell well was collected and later analyzed for
the presence of LDH to ascertain cell death. Meanwhile, SMC or EC from each cell well
were rinsed once with PBS, detached by treatment with 1% trypsin/EDTA, and collected
in aliquots. The number of cells in each aliquot was then determined using a Coulter
Counter (Model ZM, Hiahleah, FL).

Cell Migration
SMC or EC were collected and seeded in Nunc 2-well chamber slides at near confluent
densities (approximately 70,000/cm2). They were then incubated for an attachment period

42

of 48 hours. A second set of cells was incubated for an additional 2 hours in 10 pg/mL
mitomycin C. The purpose of the mitomycin was to inhibit the potentially confounding
effect of cell proliferation on cell migration.

All cells were then rinsed with PBS, treated with 8-MOP, and exposed to light in the
same manner as described previously. Cells treated with 0 pg/mL 8-MOP and exposed to
visible light served as the control cells for these experiments. Before the 8-MOP media
was aspirated and replaced with fresh growth media, a sterile wound was created across
the middle of the well using a sterile blade, and the cells on one side of the wound were
completely removed. On the specified days, the appropriate cells were rinsed with PBS,
fixed with 10% formalin, and stored in PBS. At a later time, they were stained with 2.5%
(v/v) crystal violet for 1 minute, rinsed twice with PBS, and then examined and
photographed under a light microscope.

Cell Morphology
SMC were collected and seeded in Nunc 2-well chamber slides at a density of
approximately 10,000 to 20,000/cm2. They were then incubated for an attachment period
of 24 hours. Afterwards, the cells were rinsed with PBS, treated with 8-MOP, exposed to
light, incubated, and maintained in the same manner as described in the Experimental
Protocol section. On the specified days, the appropriate cells were rinsed with PBS, fixed
with 10% formalin, and stored in PBS. At a later time, they were stained with 2.5% (v/v)
crystal violet for 1 minute, rinsed twice with PBS, and then examined and photographed
under a light microscope.
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Cell Sizeb
SMC and EC were collected and seeded in polystyrene 12-well plates at a density of
5,000 to 10,000/cm2 and allowed to attach over a 24 hour period. Treated cells were
incubated with 20 pg/mL 8-MOP for 30 minutes in the dark and then exposed to 12.0
J/cm2 447 nm visible light. As in other experiments, cells treated with 8-MOP but not
exposed to light served as control cells. Cells neither treated with 8-MOP nor exposed to
light and cells not treated with 8-MOP but exposed to light served as additional controls
for this set of experiments.

Cell size was measured with a Coulter Counter equipped with a Channelyzer (Coulter,
Hiahleah, FL) on days 3, 5, 7, 10, and 14 following the initiation of each experiment.
SMC or EC from the cell wells were rinsed once with PBS, detached by treatment with
1% trypsin/EDTA, and then collected in 500 pL aliquots. The sizes of 104 cells per
aliquot were measured and recorded.

Photoadduct Formationb
SMC and EC were collected and seeded in polystyrene 12-well plates at a density of
5,000 to 10,000/cm2. The cells were then incubated with 20 pg/mL of 8-MOP including
trace amounts of [3H]8-MOP (specific activity = 83 Ci/mmol; Amersham International,
Arlington Heights, IL) for 30 minutes in the dark and irradiated with 32.0 J/cm2 447 nm
visible light. Afterwards, the cells were trypsinized and suspended in 500 pL of 50

b Studies performed with the help of Xiu-Jie Wang and Francis Gasparro.
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mmol/L TRIS/150 mmol/L NaCl/100 mmol/L EDTA (pH 8), and the DNA was isolated
as described previously (Bevilacqua et al., 1991; Olack et al., 1993). DNA concentration
was determined by UV spectroscopy (LKB UltroSpec II), and the molar concentration in
terms of nucleotide units (base pairs) was computed from the absorbance at 260 and 280
nm.

The DNA was hydrolyzed enzymatically with 1 Unit/mL Pi nuclease and 0.1 Unit/mL
DNase I in water and then applied to an ODS reversed phase column (Regis Rexchrome,
4.6x250 mm; 5 micron, Morton Grove IL) for analysis. The [3H] 8-MOP photoadducts
(4',5' monoadducts; 3,4 monoadducts; and cross-links) were detected by scintillation
analysis of HPLC fractions collected during the analysis of enzymatically hydrolyzed
DNA isolated from cells.

Statistical Analysis
Statistical analyses (ANOVA and Student’s t Test) were performed using Systat for
Windows (Evanston, IL) and Sigmaplot (Jandel, San Rafael, CA).
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7.

Results

SMC Proliferation
The effects of 12.0 J/cm2 447 nm visible light-activated 8-MOP on SMC proliferation are
shown in the following representative growth curves (Figures 7-1, 7-2, and 7-3). The
lowest dose of 8-MOP (1 pg/mL) had no effect on SMC proliferation (Figure 7-1). The
intermediate dose of 8-MOP (20 pg/mL) yielded transient and reversible inhibition of
SMC proliferation, as evidenced by the recovery in the growth curve (Figure 7-2). The
highest dose of 8-MOP (50 pg/mL) was cytotoxic to the SMC (Figure 7-3). The growth
of SMC treated with drug or light alone at each dose was not significantly different from
control, untreated SMC (data not shown). The results of triplicate experiments per drug
dose were combined and expressed as percent recovery for days 3, 5, 7, and 10 (Figure 74), where percent recovery represents the number of cells per aliquot divided by the
number of cells in the corresponding control aliquot. Differences in percent recovery
between cells treated with 1 pg/mL and the two higher doses were statistically significant
(p<0.05).
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g/mL 8-MOP

xlOOO cells/well

SMC; 1

day

Figure 7-1. Proliferation curves for SMC treated at 1 fig/mL 8-MOP both with and without light. D = drug;
L = light; hence, control cells are represented by dark triangles and treated cells by clear triangles. No
difference is seen between control and treated cells.
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SMC; 20 fig/mL 8-MOP
r

xlOOO cells/well

1 200

day

Figure 7-2. Proliferation curves for SMC treated at 20 |ig/mL 8-MOP both with and without light. D = drug;
L = light; hence, control cells are represented by dark triangles and treated cells by clear triangles. Transient
and reversible inhibition of SMC proliferation is evidenced by the recovery in the growth curve for treated
cells.
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xlOOO cells/well

SMC; 50 ^g/mL 8-MOP

Figure 7-3. Proliferation curves for SMC treated at 50 gg/mL 8-MOP both with and without light. D = drug
L = light; hence, control cells are represented by dark triangles and treated cells by clear triangles.
Treatment at this dose of 8-MOP appears to be cytotoxic to the SMC as no recovery is seen in the growth
curve for treated cells.
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Effects of 8 —MOP on SMC at
1, 20, and 50 yUg/mL 8-MOP
1 ^g/ml
20 /ig/ml
50 gig/ml

100

CD

>

O

CD
CD
i

12

3

4

5

8

9

1011

1 2

day
Figure 7-4. Summary graph of triplicate experiments performed on SMC at 1, 20, and 50 pg/mL 8-MOP.
Percent recovery = number of treated cells/number of control cells. No effect is apparent at 1 pg/mL 8MOP. Inhibition with gradual recovery of SMC proliferation is seen at 20 pg/mL 8-MOP. Cell death is seen
at 50 pg/mL 8-MOP.
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EC Proliferation
The effects of 12.0 J/cm2 447 nm visible light-activated 8-MOP on EC proliferation are
shown in the following representative growth curves (Figures 7-5, 7-6, and 7-7). As seen
in the SMC experiments, the lowest dose of 8-MOP (1 pg/mL) had no effect on EC
proliferation (Figure 7-5). Likewise, the growth of EC treated with drug or light alone at
each dose was not significantly different from control, untreated EC (data not shown). At
both the intermediate and highest doses of 8-MOP (20 and 50 pg/mL, respectively),
however, inhibition of EC proliferation was transient and reversible, as evidenced by the
recovery in the growth curves (Figures 7-6 and 7-7). The results of triplicate experiments
per drug dose were combined and expressed as percent recovery for days 3, 5, 7, and 10
(Figure 7-8), where percent recovery represents the number of cells per aliquot divided by
the number of cells in the corresponding control aliquot. Differences in percent recovery
between cells treated with 1 pg/mL and the two higher doses were statistically significant
(p<0.05) only for day 5.
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EC; 1 fj,g/mL 8-MOP

xlOOO cells/well

800 r

Figure 7-5. Proliferation curves for EC treated at 1 pg/mL 8-MOP both with and without light. D = drug; L
= light; hence, control cells are represented by dark triangles and treated cells by clear triangles. No
difference is seen between control and treated cells.
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EC; 20 fig/mL 8-MOP

Figure 7-6. Proliferation curves for EC treated at 20 pg/mL 8-MOP both with and without light. D = drug;
L = light; hence, control cells are represented by dark triangles and treated cells by clear triangles. Transient
and rapidly reversible inhibition of EC proliferation is evidenced by the recovery in the growth curve for
treated cells.
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xlOOO cells/well

EC; 50 yUg/mL 8-MOP

Figure 7-7. Proliferation curves for EC treated at 50 (ig/mL 8-MOP both with and without light. D = drug;
L = light; hence, control cells are represented by dark triangles and treated cells by clear triangles. Transient
and rapidly reversible inhibition of EC proliferation is evidenced by the recovery in the growth curve for
treated cells.
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Effects of 8 —MOP on EC at
1, 20, and 50 /xg/mL 8 —MOP
1 ^g/ml
■_120 Mg/ml
50 /jlg/ml
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Figure 7-8. Summary graph of triplicate experiments performed on EC at 1, 20, and 50 pg/mL 8-MOP.
Percent recovery = number of treated cells/number of control cells. No effect is apparent at 1 pg/mL 8MOP. Inhibition with rapid recovery of EC proliferation is seen at both 20 and 50 pg/mL 8-MOP.
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Cell Migration
Figure 7-9 demonstrates SMC migration on day 3 following treatment with 0, 1, 20, and
50 gg/mL 8-MOP. The photographs reveal that no concentration of 8-MOP was capable
of producing an inhibitory effect on SMC migration. Studies on EC also demonstrated a
lack of effect on cell migration, even at highest dose (data not shown). The extent of
migration observed in cells treated with mitomycin did not differ significantly from that
of cells not treated with mitomycin.

SMC Migration

0 fig/ml

1 pg/ml

20|iig/ml

50pg/ml

Figure 7-9. Extent of SMC migration seen on day 3 after treatment with 0, 1,20, and 50 (ig/mL 8-MOP and
12 J/cm2 447 nm light. No difference is apparent among these cells treated at different 8-MOP
concentrations.
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Cell Morphology
Figures 7-10, 7-11, and 7-12 represent a series of photographs which depict the
morphology of treated and control SMC at days 5, 7, and 10. The photographs reveal cell
densities consistent with those expected based on the SMC proliferation data. The
majority of cells in all samples appeared healthy. While no difference in morphology was
appreciated between cells treated with 1 pg/mL 8-MOP and control cells (Figure 7-10),
morphologic examination of cells treated at 20 and 50 pg/mL 8-MOP revealed cells
which were larger and phenotypically different from their respective controls (Figures 711 and 7-12). Additionally, this difference in morphology appeared to resolve over time
in cells treated with 20 pg/mL 8-MOP (Figure 7-11) but not in those treated with 50
pg/mL 8-MOP (Figure 7-12).
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1 pg/ml 8-MOP

Day 5

Day 7

Day 10

Figure 7-10. SMC morphology on days 5, 7, and 10 following treatment with 1 pg/mL 8-MOP. Cell
densities are consistent with those expected based on SMC proliferation data. No difference in morphology
is appreciable between control and treated cells.
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20 (xg/ml 8-MOP

Day 5

Day 7

Day 10

Figure 7-11. SMC morphology on days 5, 7, and 10 following treatment with 20 pg/mL 8-MOP. Cell
densities are consistent with those expected based on SMC proliferation data. Treated cells appear larger
and phenotypically different from control cells on day 5. This difference in morphology appears to begin to
resolve by day 10.
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50 pg/ml 8-MOP

Day 5

Day 7

Day 10

Figure 7-12. SMC morphology on days 5, 7, and 10 following treatment with 50 pg/mL 8-MOP. Cell
densities are consistent with those expected based on SMC proliferation data. Treated cells appear larger
and phenotypically different from control cells on day 5. This difference in morphology appears to persist.
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Cell Size
Figure 7-13 shows a series of size distribution diagrams. The x-axis corresponds to the
size of individual cells (measured in femtoliters, fL) while the y-axis represents the
number of cells in each sample measured at that particular size. For each day, the size
distribution for untreated control cells (-D/-L), 8-MOP only-treated control cells (+D/-L),
visible light only-treated control cells (-D/+L), and cells treated with both 8-MOP and
visible light (+D/+L) are shown. At any given day, the vertical dotted line represents the
average (mode) size of the three different groups of control cells.

On day 3, the average size of untreated SMC was 1.70 fL, while the average size of
untreated EC was 1.32 fL. For both SMC and EC, treatment with either 8-MOP or visible
light alone failed to induce any significant change in cell size. Treatment with both 8MOP and visible light, on the other hand, resulted in an increase in average cell size. This
increase in cell size was maintained in SMC over the time course studied, with only a
slight decrease in cell size detected by day 14. The increase in EC size, however, rapidly
resolved with a return to control sizes by day 10.

These changes in cell size were plotted over a time course (Figure 7-14). For SMC,
average cell size increased to 2.50 fL by day 5 and then plateaued at 3.20 fL by day 10. A
different pattern was observed in EC, which increased in average size to 3.80 fL by day 5
but returned to near control size (1.30 fL) by day 10.

Figure 7-13. Cell size distribution diagrams, x-axis = size of cells, measured in femtoliters (fL); y-axis =
number of cells measured at the given size. D = drug; L = light. The four rows represent size distribution
diagrams for untreated control cells (-D/-L), 8-MOP only-treated control cells (+D/-L), visible light onlytreated control cells (-D/+L), and 8-MOP and visible light-treated cells (+D/+L). The vertical dotted line
represents the average (mode) size of the three different groups of control cells.
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Photoadduct Formation
SMC and EC treated with 20 |ig/mL 8-MOP and 32 J/cm2 447 nm light revealed
comparable levels of photoadduct formation. 110 adducts per million base pairs were
found in SMC, while 200 adducts per million base pairs were seen in EC. Relative
formation of the different types of photoadducts (4’, 5’-monoadducts; 3, 4-monoadducts;
and crosslinks) were similar between the two cell types as demonstrated in the following
high-performance liquid chromatography (HPLC) curves (Figure 7-15).

CPM

Fraction Number

Figure 7-15. Graphs comparing photoadduct formation in EC and SMC. CPM = counts per minute. Lateeluting 8-MOP-thymdine photoadducts were detected by liquid scintillation analysis. Photoadduct
distributions between the two cell types were similar.
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8.

Discussion

Discussion of Results
Cell Proliferation. The present study demonstrates that 8-MOP photoactivated with 447

nm visible light can reversibly inhibit both SMC and EC proliferation in vitro in a dosedependent fashion. The study also reveals that different 8-MOP dosages cause a range of
effects in SMC proliferation, from no effect to reversible cytostasis to cytotoxicity. These
selected dosages appear to have significantly attenuated effects on EC compared to SMC.

The rapidly reversible inhibition of EC proliferation observed in the experiments, even at
high 8-MOP concentrations, bears clinical significance in light of previous studies which
have demonstrated that a functionally intact endothelium contributes to the inhibition of
SMC proliferation (Ip et al., 1991). The fact that photochemotherapy with 8-MOP and
visible light can selectively inhibit SMC proliferation without causing damage to EC
immediately suggests this treatment regimen as a potential solution to the problem of post¬
angioplasty restenosis.

Cell Migration. As intimal hyperplasia involves not only SMC proliferation but also

SMC migration, experiments evaluating the effects of 8-MOP photoactivated with 447
nm visible light on cell migration were performed. Unlike the effects observed in SMC
and EC proliferation, however, no inhibition of either SMC or EC migration was found.
Nevertheless, while both SMC migration and proliferation are involved in the neointima
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formation which occurs after angioplasty, it is known that SMC proliferation contributes
more materially to the process.

It has been estimated that only about one half of the SMC which migrate into the intima
after angioplasty undergo further proliferation. The remaining SMC do not. Those SMC
which do continue to proliferate undergo approximately three rounds of division, thereby
constituting eight ninths of the final neointimal cell population (Clowes and Schwartz,
1985). This suggests that SMC proliferation has a significantly greater impact on
restenosis than SMC migration; hence, the finding that phototherapy with 8-MOP and
visible light fails to inhibit cell migration does not disqualify this treatment regimen as a
potential solution to the problem of post-angioplasty restenosis.

Cell Morphology. Despite its lack of effect on cell migration, the combination of 8-MOP

and visible light was found to affect SMC morphology. It is interesting to note that just as
different effects in SMC proliferation were observed in response to different 8-MOP
dosages, a range of effects in SMC morphology was also seen in response to different 8MOP dosages. While no morphological differences were appreciated between SMC
treated with 1 pg/mL 8-MOP and their controls, SMC treated with 20 pg/mL and 50
pg/mL 8-MOP appeared larger and phenotypically different from their respective
controls. Moreover, this difference in morphology appeared to resolve over time in the
cells treated with 20 pg/mL 8-MOP but not in those treated with 50 pg/mL. Whether this
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range of effects observed in cell morphology is somehow related to the range of effects
seen in SMC proliferation remains to be elucidated.

Cell Size. Additional studies employing a Channelyzer capable of measuring cell sizes

(volumes) were conducted to corroborate the cell enlargement induced by treatments with
8-MOP and 447 nm visible light observed in the morphology experiments. Cell size
measurements confirmed that treatment with 20 pg/mL 8-MOP causes an increase in
average cell size for both SMC and EC. Unlike the findings noted in the morphology
studies, however, the increase in SMC sizes did not resolve over time but instead
persisted. The increase in EC sizes, on the other hand, appeared to resolve by day 10.

The reason for these differences in cell size changes over time noted between the
morphology experiments and cell size experiments is unclear but may be due to the fact
that morphology studies assess cell sizes on a two-dimensional level, while a Channelyzer
measures cell sizes in three dimensions. The difference in ability of SMC and EC to
return to control sizes following the same treatment represents an important finding and
may be related to the differences observed in the cell proliferation experiments, as an
attenuated response to treatment with the same 8-MOP dosage is again observed in EC
compared to SMC.

Photoadduct formation. As anticipated, the number of photoadducts measured in SMC

and EC were within the same order of magnitude. Given the comparatively attenuated
effects of the treatments on EC proliferation and size, one might have expected fewer
photoadducts to have been found in EC than SMC. Surprisingly, the number of
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photoadducts measured in EC was nearly twice that measured in SMC. This suggests that
the attenuated effects observed in EC are not the result of the formation of fewer
photoadducts.

Potential Future Experiments
Comparison between SMC and EC proliferation curves reveals that photochemotherapy
with high doses of 8-MOP is cytotoxic to SMC but yields only transient cytostasis in EC.
The reason for these differences in response between SMC and EC to identical
photochemotherapeutic treatments remains to be determined. As it had been presumed
that inhibition of cellular proliferation could be directly related to extent photoadduct
formation, the decreased sensitivity of EC to 8-MOP treatments was initially
hypothesized to be the result of decreased photoadduct formation. The preliminary study
on photoadduct formation, however, revealed that EC forms nearly twice the number of
photoadducts as SMC.

As this observation is based on a single experiment, repeat experiments on photoadduct
formation are in order. Repeat studies may confirm that photoadduct formation is indeed
consistently greater in EC or may reveal that the difference in photoadduct formation
between SMC and EC observed in the pilot study falls within normal variance.

Assuming that the greater photoadduct formation observed in EC is genuine, experiments
designed to explicate the fact that EC are less sensitive to treatments with 8-MOP and
visible light despite more extensive photoadduct formation should be undertaken. As
differences in DNA repair rates which would allow EC to restore its proliferative

68

functionality more rapidly than SMC might account for this discrepancy, experiments
comparing photoadduct formation levels in SMC and EC over a time course could be
performed. These studies would help to characterize the DNA repair kinetics of the two
cell types and might reveal differences. Specifically, they might demonstrate that EC
possess more efficient DNA repair machinery than SMC.

However, should these experiments reveal that EC exhibit greater photoadduct formation
than SMC at all time points, the hypothesis that inhibition of cell proliferation is directly
related to extent photoadduct formation would have to be challenged. Further
experimentation might reveal that extent photoadduct formation is only one of a number
of factors which contribute to the inhibition of cell proliferation.

Another issue which could potentially be addressed in future experiments is the question
of whether photochemotherapy with 8-MOP and visible light would yield similar results
in human coronary cells. The difference in response seen between bovine aortic SMC and
EC already suggests that dissimilar cell types may respond differently to the same
treatment. Thus, studies performed on human coronary cells in vitro would be useful.

While photochemotherapy with 8-MOP and visible light has been shown to dosedependently inhibit proliferation of SMC and EC in vitro, it would also be valuable to
evaluate the effects of this treatment regimen on vascular cells in vivo. The experimental
methods employed in the present study artificially isolate SMC from EC. Recall that in
the normal coronary artery, these cells are separated by only a thin, fenestrated internal
elastic membrane (see “The Normal Coronary Artery,” Chapter 1). Thus, in the live
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model, these cells interact with each other and affect one another’s functional capacities.
Hence, in vivo studies designed to corroborate the beneficial effects of phototherapy with
8-MOP suggested by our in vitro experiments would also prove useful.

Finally, studies examining the effects of visible light-activated 8-MOP on cell functions
other than proliferation and migration might prove beneficial. For example, experiments
designed to assess the effects of these treatment regimens on the ability of SMC and EC
to synthesize proteins could be performed. If protein synthesis were inhibited, follow-up
studies could be performed to assess recovery of synthetic function. These types of
experiments on the effects of visible light-activated 8-MOP on vascular cell function
would further elucidate the suitability of this treatment modality for clinical trials.

Significance of Results
The clinical significance of the present study is related to the established long-term safety
of 8-MOP, the availability of 447 nm lasers, the ability to target therapy to the angioplasty
site, and the potentially reversible nature of the effects of therapy.

As mentioned previously, 8-MOP exhibits a rapid clearance which results in minimal
clinical phototoxicity. Its common use in the treatment of dermatologic diseases has
established its long-term safety. Moreover, the significant reduction in extent of crosslink
formation seen at photoactivation with 447 nm light may render photochemotherapy with
8-MOP at this wavelength a greater therapeutic index.
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Perhaps this reduction in crosslink formation contributes to the rapidity of the
proliferative functional recovery observed in SMC treated with intermediate dose (20
pg/mL ) 8-MOP. The cytostatic effect of this treatment regimen without cytotoxicity
represents a theoretical advantage over cytotoxic therapies for the prevention of
restenosis. SMC necrosis caused by cytotoxic therapies could compromise the mechanical
integrity of the arterial wall and result in the formation of an aneurysm. Moreover,
cytokines released by damaged or dying SMC could stimulate a secondary local
inflammatory response and cause an exacerbation of the cellular proliferative response
(Sumpio et al., 1994).

As the migration and proliferation of SMC stimulated by angioplasty begins as early as
24 to 48 hours after the procedure and lasts for approximately one week (Forrester et ah,
1991; Ip et ah, 1991), a transient, reversible inhibition of SMC proliferation may
represent an optimal solution to the problem of post-angioplasty restenosis. The present
study demonstrates that 8-MOP photoactivated with visible light is capable of inhibiting
SMC proliferation, presumably via photoadduct formation. Excision of these
photoadducts by DNA repair mechanisms would allow for the eventual return of
proliferative capacity and could result in the restoration of SMC functionality at a time
when the stimulus to proliferate has waned.

Currently available technology permits photochemotherapy with 8-MOP and visible light
to be directed to a discrete site on the vessel wall by means of local drug and/or light
delivery. While 8-MOP has traditionally been administered systemically (both orally and
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intravenously) for other therapeutic applications, high local concentrations of the drug
could be attained via intra-arterial administration with a double-balloon catheter.

double balloons
Figure 8-1. Schematic of a double-balloon catheter demonstrating how high local concentrations of drug
could be achieved with this device.

Intra-arterial light irradiation of a segment of the vessel wall could then be achieved using
a recently described fiber-optic balloon catheter, which has been clinically evaluated for
simultaneous balloon dilatation and arterial wall irradiation (Spears et al., 1990).
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9.

Conclusion

In conclusion, SMC proliferation constitutes a major mechanism by which restenosis
after angioplasty occurs. A therapeutic regimen capable of inhibiting SMC proliferation
both selectively and reversibly might represent an ideal solution to the problem of post¬
angioplasty restenosis. As the present study demonstrates that photochemotherapy with 8MOP and visible light possesses these characteristics, this treatment regimen may
represent a novel approach to the prevention of post-angioplasty restenosis.
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